Hengrui Therapeutics (HTI) is a recently formed biopharmaceutical company based in Princeton, N.J., focused on developing and commercializing innovative oncology and immuno-oncology medicines. Its drug pipeline consists of multiple clinical-stage oncology and immuno-oncology assets. The company announced a $100 million investment intended to advance clinical trials across its current areas of pharmaceutical research and development. Management says the proceeds will enable a swift build-up of HTI’s infrastructure to support execution of its development projects in the U.S. and globally. HTI positions its corporate mission around fighting cancer and other serious diseases worldwide. Company leadership, including Chairman Piaoyang Sun and CEO Adam Zong, framed the funding as laying a foundation for long-term growth and to support a robust clinical-stage pipeline.

Total raised

$100M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2016